Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma

Mol Oncol. 2022 Oct;16(20):3703-3719. doi: 10.1002/1878-0261.13305. Epub 2022 Sep 5.

Abstract

Cancer stem-like cells (CSLC) are considered a major contributor to the development and progression of hepatocellular carcinoma (HCC). Previous studies indicated that CSLC are characterized by resistance to ferroptosis, a type of lipid peroxidation-dependent cell death. Here, we identified a set of ferroptosis-related stemness genes (FRSG) and found that these genes may be involved in immune infiltration in HCC. A four-FRSG (CDKN2A, GABARAPL1, HRAS, RPL8) risk model with prognostic prediction was constructed by a Cox analysis in HCC. Among these four genes, GABARAPL1 was downregulated in HCC tumor-repopulating cells (TRC; a type of CSLC). Its downregulation decreased the sensitivity of HCC TRC to erastin- or sorafenib-triggered ferroptosis. Together, we uncovered a molecular mechanism via which CSLC could achieve tolerance to ferroptosis. Further studies may provide potential therapeutic strategies targeting CSLC in HCC.

Keywords: GABARAPL1; cancer stem-like cell; ferroptosis; hepatocellular carcinoma; sorafenib.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Carcinoma, Hepatocellular* / pathology
  • Cell Death
  • Ferroptosis* / genetics
  • Humans
  • Liver Neoplasms* / pathology
  • Microtubule-Associated Proteins / metabolism
  • Sorafenib / pharmacology
  • Sorafenib / therapeutic use

Substances

  • Sorafenib
  • GABARAPL1 protein, human
  • Microtubule-Associated Proteins
  • Adaptor Proteins, Signal Transducing